The Swiss major’s partner Halozyme has revealed that the US launch for the subcutaneous version of the checkpoint inhibitor Tecentriq will be put back until 2024 following questions from the Food and Drug Administration about manufacturing processes.

The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem. 

Twelve applications with September goal dates include six novel agents but only one breakthrough designation.

The National Health Service in England says it will be the first health system in the world to roll out a subcutaneously administered formulation of Tecentriq, after the UK MHRA became the first drug regulator to approve the product.